新型嘧啶单环类非经典叶酸拮抗剂的合成及抗肿瘤活性研究

以课题组前期设计合成的非经典叶酸拮抗剂6-(4'-甲基苯乙基)-N5-氯乙酰基-2,4-二氨基哌啶并[3,2-d]嘧啶(wm-8.2)为先导化合物,将wm-8.2中的哌啶并嘧啶双环结构简化为嘧啶单环结构,以提高分子柔韧性并简化分子结构,根据6-位空间占位设计6-H和6-甲基两个系列,考察了不同桥链长度和不同芳香杂环侧链对抗肿瘤活性的影响.同时对具有叶酸抑制剂分子结构特征的关键中间体进行活性对比测定,研究了N(5)位氯乙酰基对活性的影响.两个系列目标化合物和关键中间体共36个化合物的结构均经1H NMR,13C NMR和MS确证.生物活性测定表明,6位为甲基的化合物中,具有三碳桥链及对甲基苯环侧链的6-甲基-2,4-二氨基-5-(N-(4-甲基苯基)丙基-N-(2-氯乙酰基))氨基嘧啶(6b-3)具有最好的HL-60、A549和HCT116细胞增殖抑制活性,IC50分别为0.25,0.83和0.63μmol?L^-1.化合物6b-3在N(5)位氯乙酰基取代之前的关键中间体6-甲基-2,4-二氨基-5-(N-(4-甲基苯基)丙基)氨基嘧啶(5b-3)具有最优的二氢叶酸还原酶抑制活性.总结了化合物的构效关系,并用计算机模拟进行了阐释.     

Dihydrofolate reductase: structural aspects of mechanisms of enzyme catalysis and inhibition

The mechanism of catalytic reduction of folic and dihydrofolic acids to tetrahydrofolate, which proceeds under the action of dihydrofolate reductase and the coenzyme NADPH, is considered. The roles of the enzyme active site, the coenzyme, individual amino acid residues of the enzyme, and water molecules in the catalytic reaction are discussed. Interactions of the enzyme with competitive inhibitors many of which are widely used in medicine as antitumor and antibacterial drugs are examined. The factors controlling the selectivity of inhibitor binding to bacterial forms of the enzyme are analyzed. The results of X-ray diffraction and NMR spectroscopic studies of the structures of the enzyme and its complexes with the substrate and inhibitors are surveyed. The role of specific interactions and molecular motions of the protein and ligands in the mechanism of catalysis and in the binding of the ligands to the enzyme is discussed.     

Spectroscopic Analysis of Folate Binding to Thymidylate Synthase Active Site

The fluorescence properties of folate binding to thymidylate synthase (TS) were analyzed. Two antifolates with different binding modes to the TS active site were the ligands. Intrinsic tryptophan fluorescence was used to evaluate the binding of both antifolates to the wild-type TS and a mutant Escherichia coli TS (K48Q) that is impaired in folate binding. During titration of wild-type TS with PDDF, tryptophan fluorescence was quenched at 330 nm, which was accompanied by an increase in emission at 379 nm, suggesting an energy transfer process from a tryptophan in the TS active site to the folate analogue. Energy transfer was not observed with the mutant TS, as expected. Tryptophan emission is a very useful tool to test for substrate-like inhibitors with biological activity.     

叶酸拮抗剂Alimta的合成

吡咯并[2,3-d]嘧啶类叶酸拮抗剂Alimta (1)是一种多靶向的抗癌药物, 本工作建立了新的方法全合成该药物. 通过Friedel-Crafts反应、黄鸣龙反应制备了4-(4-乙氧基-4-氧正丁基)苯甲酸乙酯(5), 收率为36.6%. 然后采用KBH₄/LiBr对5选择性还原, 再经氧化、成环等反应最终合成该药. 总收率4.8%.     

Supramolecular hydrogen‐bonding patterns in salts of the antifolate drugs trimethoprim and pyrimethamine

Nine salts of the antifolate drugs trimethoprim and pyrimethamine, namely, trimethoprimium [or 2,4‐diamino‐5‐(3,4,5‐trimethoxybenzyl)pyrimidin‐1‐ium] 2,5‐dichlorothiophene‐3‐carboxylate monohydrate (TMPDCTPC, 1:1), C₁₄H₁₉N₄O₃⁺·C₅HCl₂O₂S⁻, ( I ), trimethoprimium 3‐bromothiophene‐2‐carboxylate monohydrate, (TMPBTPC, 1:1:1), C₁₄H₁₉N₄O₃⁺·C₅H₂BrO₂S⁻·H₂O, ( II ), trimethoprimium 3‐chlorothiophene‐2‐carboxylate monohydrate (TMPCTPC, 1:1:1), C₁₄H₁₉N₄O₃⁺·C₅H₂ClO₂S⁻·H₂O, ( III ), trimethoprimium 5‐methylthiophene‐2‐carboxylate monohydrate (TMPMTPC, 1:1:1), C₁₄H₁₉N₄O₃⁺·C₆H₅O₂S⁻·H₂O, ( IV ), trimethoprimium anthracene‐9‐carboxylate sesquihydrate (TMPAC, 2:2:3), C₁₄H₁₉N₄O₃⁺·C₁₅H₉O₂⁻·1.5H₂O, ( V ), pyrimethaminium [or 2,4‐diamino‐5‐(4‐chlorophenyl)‐6‐ethylpyrimidin‐1‐ium] 2,5‐dichlorothiophene‐3‐carboxylate (PMNDCTPC, 1:1), C₁₂H₁₄ClN₄⁺·C₅HCl₂O₂S⁻, ( VI ), pyrimethaminium 5‐bromothiophene‐2‐carboxylate (PMNBTPC, 1:1), C₁₂H₁₄ClN₄⁺·C₅H₂BrO₂S⁻, ( VII ), pyrimethaminium anthracene‐9‐carboxylate ethanol monosolvate monohydrate (PMNAC, 1:1:1:1), C₁₂H₁₄ClN₄⁺·C₁₅H₉O₂⁻·C₂H₅OH·H₂O, ( VIII ), and bis(pyrimethaminium) naphthalene‐1,5‐disulfonate (PMNNSA, 2:1), 2C₁₂H₁₄ClN₄⁺·C₁₀H₆O₆S₂²⁻, ( IX ), have been prepared and characterized by single‐crystal X‐ray diffraction. In all the crystal structures, the pyrimidine N1 atom is protonated. In salts ( I )–( III ) and ( VI )–( IX ), the 2‐aminopyrimidinium cation interacts with the corresponding anion via a pair of N—H…O hydrogen bonds, generating the robust R₂²(8) supramolecular heterosynthon. In salt ( IV ), instead of forming the R₂²(8) heterosynthon, the carboxylate group bridges two pyrimidinium cations via N—H…O hydrogen bonds. In salt ( V ), one of the carboxylate O atoms bridges the N1—H group and a 2‐amino H atom of the pyrimidinium cation to form a smaller R₂¹(6) ring instead of the R₂²(8) ring. In salt ( IX ), the sulfonate O atoms mimic the role of carboxylate O atoms in forming an R₂²(8) ring motif. In salts ( II )–( IX ), the pyrimidinium cation forms base pairs via a pair of N—H…N hydrogen bonds, generating a ring motif [R₂²(8) homosynthon]. Compounds ( II ) and ( III ) are isomorphous. The quadruple DDAA (D = hydrogen‐bond donor and A = hydrogen‐bond acceptor) array is observed in ( I ). In salts ( II )–( IV ) and ( VI )–( IX ), quadruple DADA arrays are present. In salts ( VI ) and ( VII ), both DADA and DDAA arrays co‐exist. The crystal structures are further stabilized by π–π stacking interactions [in ( I ), ( V ) and ( VII )–( IX )], C—H…π interactions [in ( IV )–( V ) and ( VII )–( IX )], C—Br…π interactions [in ( II )] and C—Cl…π interactions [in ( I ), ( III ) and ( VI )]. Cl…O and Cl…Cl halogen‐bond interactions are present in ( I ) and ( VI ), with distances and angles of 3.0020 (18) and 3.5159 (16) Å, and 165.56 (10) and 154.81 (11)°, respectively.     

2-位或4-位取代吡啶并嘧啶类非经典叶酸拮抗剂的合成及抗肿瘤活性

以非经典叶酸拮抗剂2,4-二氨基-6-(4-甲基苯基)乙基吡啶并[3,2-d]嘧啶(wm-5b)及其侧链简化产物2,4-二氨基吡啶并[3,2-d]嘧啶为先导化合物, 选取具有抗肿瘤活性的基团, 通过微波法高效合成了2-位或4-位取代吡啶并嘧啶类非经典叶酸拮抗剂, 研究了2-位及4-位取代基对抗肿瘤活性的影响, 为非经典叶酸拮抗剂的设计合成提供了更多的理论依据. 目标化合物的结构均经核磁共振波谱(NMR)和质谱(MS)确证. 生物活性测定结果表明, 所有目标化合物均具有抗肿瘤活性, 其中, 6-(4-甲基苯基)乙基-4-氨基-2-(3-氯-4-氟苯基)氨基吡啶并[3,2-d]嘧啶(6b)对HL-60细胞的IC₅₀=(4.09±0.48) μmol/L, 对A549细胞的IC₅₀=(17.99±7.20) μmol/L, 而对HCT116细胞的IC₅₀=(14.52±4.74) μmol/L; 部分目标化合物具有二氢叶酸还原酶抑制活性. 此外, 对部分目标化合物和先导物进行了二氢叶酸还原酶晶体结构的分子对接, 对活性结果和构效关系从分子水平上进行解释.